The ethical and practical challenges of value-based cancer care at the patient's bedside

JAMA Oncology

Volumn 2, Issue 7, 2016, Pages 860-861

  Goldstein, Daniel A ^a,b  

^a RABIN MEDICAL CENTER   (Israel)

^b EMORY UNIVERSITY   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ECONOMICS; ETHICS; HEALTH CARE COST; HEALTH ECONOMICS; HOSPITAL; HUMAN; MEDICAL ETHICS; NEOPLASM; PATIENT;

ECONOMICS, HOSPITAL; ETHICS, MEDICAL; HEALTH CARE COSTS; HOSPITALS; HUMANS; NEOPLASMS; PATIENTS;

EID: 85010460635     PISSN: 23742437     EISSN: 23742445     Source Type: Journal    
DOI: 10.1001/jamaoncol.2016.0535     Document Type: Short Survey

References (7)

1. Thatcher N, Hirsch FR, Luft AV, et al; SQUIRE Investigators. Necitumumab plus gemcitabine and cisplatin versus gemcitabine and cisplatin alone as first-line therapy in patients with stage IV squamous non-small-cell lung cancer (SQUIRE): an open-label, randomised, controlled phase 3 trial. Lancet Oncol. 2015;16(7):763-774.
2. Goldstein DA, Chen Q, Ayer T, et al. Necitumumab in metastatic squamous cell lung cancer: establishing a value-based cost. JAMA Oncol. 2015;1(9):1293-1300.
3. Loftus P. Lilly's lung-cancer drug Portrazza to cost $11,430 a month. The Wall Street Journal. December 11, 2015. http://www.wsj.com/articles/lillys-lung-cancer-drug-portrazza-to-cost-11-430-a-month-1449867424. Accessed April 3, 2016.
4. Sulmasy D, Moy B. Debating the oncologist's role in defining the value of cancer care: our duty is to our patients. J Clin Oncol. 2014;32(36):4039-4041.
5. Jagsi R. Debating the oncologist's role in defining the value of cancer care: we have a duty to society. J Clin Oncol. 2014;32(36):4035-4038.
6. Saltz LB. The cost and value of anti-epidermal growth factor receptor therapies: let's not be rash. JAMA Oncol. 2015;1(2):141-142.
7. Goldstein DA, El-Rayes BF. Considering efficacy and cost, where does ramucirumab fit in the management of metastatic colorectal cancer? Oncologist. 2015;20(9):981-982.